

Decision Point: GF/B40/EDP09: Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation

The Board:

1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B40/ERO7 (“Table 1”);
2. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1: Secretariat’s Recommendation on Funding from the 2017-2019 Allocation - Please note that each country name is linked to the extranet site where supporting documents are available for review

N	Applicant	Disease Component	Grant Name ¹	Grant End Date	Currency	Total Program Budget	Catalytic Funds in Grant	Domestic Commitment ²	Unfunded Quality Demand
1	Egypt	TB/HIV	EGY-C-UNDP	31-03-2022	USD	2,058,336	0	N/A	3,883,661
2	Guatemala	TB	GTM-T-MSPAS	30-06-2022	USD	5,849,483	0	9,206,207	161,884
3	Multicountry Caribbean MCC	TB/HIV	QRB-C-OECS	31-03-2022	USD	3,550,000	0	N/A	460,000
4	Armenia	TB/HIV	ARM-C-MOH	30-09-2021	USD	7,923,240 ³	0	20,800,000	914,987

¹ The Grant names are subject to change based on the ISO code.

² Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies. Co-financing requirements do not apply to multicountry grants.

³ Total composition: US\$4,484,315 for TB (already approved by the Board), US\$3,138,925 for HIV and US\$300,000 for portfolio optimization. Therefore, Board approval is sought for US\$3,138,925 for HIV under GF/B40/EDP09 and US\$300,000 for portfolio optimization under GF/B40/EDP10